Biotechnology - Amgen

Filter

Current filters:

Amgen

Popular Filters

1 to 25 of 124 results

Amgen updates on Prolia in postmenopausal osteoporosis

Amgen updates on Prolia in postmenopausal osteoporosis

16-09-2014

USA-based Amgen has released results from a new exploratory analysis of the open-label extension study…

AmgenAnti-Arthritics/RheumaticsBiotechnologyProliaResearchWomen's Health

Green Cross Neulapeg biosimilar approved in South Korea

28-08-2014

South Korea’s Green Cross says that the country’s Ministry of Food and Drug Safety has granted marketing…

AmgenAsia-PacificBiosimilarsBiotechnologyGreen CrossNeulapegNeulastaOncologyRegulation

FDA priority review for Amgen’s ivabradine in CHF

FDA priority review for Amgen’s ivabradine in CHF

27-08-2014

The US Food and Drug Administration has granted priority review designation for US biotech giant Amgen’s…

AmgenBiotechnologyCardio-vascularivabradineRegulationServierUSA

Further positive Ph III results for Amgen’s AMG 416 in secondary hyperparathyroidism

Further positive Ph III results for Amgen’s AMG 416 in secondary hyperparathyroidism

19-08-2014

USA-based Amgen has released positive data from a second placebo-controlled Phase III study evaluating…

AMG 416AmgenBiotechnologyClinical researchHemodialysisNephrology and HepatologyResearchUSA

Amgen issues voluntary recall of Aranesp prefilled syringes in certain countries

Amgen issues voluntary recall of Aranesp prefilled syringes in certain countries

15-08-2014

USA-based Amgen initiated a voluntary recall on June 26 for nine packaged lots of anemia drug Aranesp…

AmgenAnemiaAranespBiotechnologyMarkets & MarketingOncologyRegulation

Amgen’s Kyprolis failed to meet primary endpoint in multiple myeloma trial

Amgen’s Kyprolis failed to meet primary endpoint in multiple myeloma trial

14-08-2014

USA-based Amgen, the world’s leading independent biotech firm, and its subsidiary Onyx Pharmaceuticals,…

Advanced refractory multiple myelomaAmgenBiotechnologyKyprolisOncologyOnyx PharmaceuticalsResearchUSA

Amgen’s 2nd-qtr beats expectations, but firm slashes workforce

Amgen’s 2nd-qtr beats expectations, but firm slashes workforce

30-07-2014

Amgen, the largest global independent biotech firm, reported a 23% leap in second-quarter 2014 profit…

AmgenBiotechnologyFinancialManagement

Sandoz application for biosimilar Neupogen accepted by US FDA

25-07-2014

The US Food and Drug Administration has accepted the Biologics License Application for filgrastim, which…

AmgenBiosimilarsBiotechnologyFilgrastimNeupogenNovartisOncologyRegulationSandozUSAZarzio

Amgen’s evolocumab to become gold standard among add-on statin therapies

Amgen’s evolocumab to become gold standard among add-on statin therapies

22-07-2014

Leading independent biotech firm Amgen’s investigational compound evolocumab (AMG-145) is set to become…

AmgenBiotechnologyCardio-vascularCardiovascular diseaseEuropeevolocumabMarkets & MarketingUSA

BIND Thera and Amgen end their Accurin collaboration

BIND Thera and Amgen end their Accurin collaboration

03-07-2014

US clinical stage drug developer BIND Therapeutics saw its shares plunge 15.8% to $10.84 in after-hours…

AccurinsAmgenBIND TherapeuticsBiotechnologyLicensingOncology

Breakthrough status for Amgen’s blinatumomab in ALL

01-07-2014

USA-based Amgen, the world's largest independent biotech firm, says that the US Food and Drug Administration…

AmgenBiotechnologyblinatumomabOncologyRegulationUSA

Amgen’s Vectibix approved for colorectal cancer by FDA

Amgen’s Vectibix approved for colorectal cancer by FDA

27-05-2014

USA-based Amgen, the world's leading independent biotech firm, has announced that the US Food and Drug…

AmgenBiotechnologyChemotherapy regimensMetastatic colorectal cancerOncologyRegulationUSAVectibix

Amgen names Steven Galson, Senior Vice President, Global Regulatory Affairs and Safety

Amgen names Steven Galson, Senior Vice President, Global Regulatory Affairs and Safety

14-05-2014

US biotech firm Amgen has announced the appointment of Steven Galson to the position of senior vice president,…

AmgenBiotechnologyBoardroomUSA

Evolocumab combined with statin results in further reduction of cholesterol levels

Evolocumab combined with statin results in further reduction of cholesterol levels

14-05-2014

Among patients with high cholesterol receiving moderate- or high-intensity statin therapy, the addition…

AmgenBiotechnologyCardio-vascularevolocumabResearch

Amgen and AstraZeneca’s brodalumab meets all endpoints in Ph III study

Amgen and AstraZeneca’s brodalumab meets all endpoints in Ph III study

10-05-2014

Anglo-Swedish drug major AstraZeneca and the USA’s Amgen have announced that the Phase III AMAGINE-1…

AmgenAstraZenecaBiotechnologybrodalumabInflammatory diseasesResearch

Oxford BioTherapeutics uses Amgen’s Xenomouse antibodies for breast cancer

07-05-2014

UK biotech company Oxford BioTherapeutics has obtained the exclusive global rights to USA-based Amgen’s…

AmgenBiotechnologyImmunoGenLicensingOncologyOxford BioTherapeutics

Amgen's 1st-qtr 2014 disappoints, as net income falls 25%

23-04-2014

Amgen, the world’s largest independent biotech firm by revenues, yesterday announced financial results…

AmgenBiotechnologyFinancialResearch

Disappointing results with Amgen’s talimogene laherparepvec in metastatic melanoma

Disappointing results with Amgen’s talimogene laherparepvec in metastatic melanoma

06-04-2014

Leading independent biotech firm Amgen has released mixed top-line results from the primary overall survival…

AmgenBiotechnologyOncologyResearchtalimogene laherparepvec

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

04-04-2014

World leading independent biotech firm Amgen revealed in a Securities and Exchange Commission filing…

AmgenAnti-Arthritics/RheumaticsBiotechnologyGlaxoSmithKlineLicensingProliaXgeva

1 to 25 of 124 results

Back to top